Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free BACK Stock Alerts

IMAC (BACK) Competitors

IMAC logo
$0.04 0.00 (0.00%)
As of 06/12/2026 02:30 PM Eastern
Compare

BACK vs. DHAC, NIVF, UPHL, BTTX, and ACONW

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), UpHealth (UPHL), Better Therapeutics (BTTX), and Aclarion (ACONW). These companies are all part of the "healthcare" industry.

How does IMAC compare to Digital Health Acquisition?

Digital Health Acquisition (NASDAQ:DHAC) and IMAC (NASDAQ:BACK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Company Net Margins Return on Equity Return on Assets
Digital Health AcquisitionN/A N/A N/A
IMAC N/A N/A -325.44%

Digital Health Acquisition has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, IMAC has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

1.0% of Digital Health Acquisition shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 6.6% of Digital Health Acquisition shares are owned by company insiders. Comparatively, 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Digital Health Acquisition has higher earnings, but lower revenue than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Digital Health AcquisitionN/AN/AN/AN/AN/A
IMAC$72.05K2.10-$9.42M-$3.12N/A

In the previous week, Digital Health Acquisition's average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Digital Health Acquisition Neutral
IMAC Neutral

Summary

IMAC beats Digital Health Acquisition on 4 of the 5 factors compared between the two stocks.

How does IMAC compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, NewGenIvf Group had 2 more articles in the media than IMAC. MarketBeat recorded 2 mentions for NewGenIvf Group and 0 mentions for IMAC. NewGenIvf Group's average media sentiment score of 1.21 beat IMAC's score of 0.00 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company Overall Sentiment
NewGenIvf Group Positive
IMAC Neutral

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
IMAC N/A N/A -325.44%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NewGenIvf Group has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, IMAC has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NewGenIvf Group has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73M0.03$9.88MN/AN/A
IMAC$72.05K2.10-$9.42M-$3.12N/A

Summary

NewGenIvf Group beats IMAC on 8 of the 10 factors compared between the two stocks.

How does IMAC compare to UpHealth?

IMAC (NASDAQ:BACK) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

5.8% of IMAC shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Comparatively, 34.2% of UpHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

IMAC has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, UpHealth has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

IMAC has higher earnings, but lower revenue than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.10-$9.42M-$3.12N/A
UpHealth$130M0.00-$56.42M$1.470.00

In the previous week, IMAC's average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company Overall Sentiment
IMAC Neutral
UpHealth Neutral

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
UpHealth N/A N/A N/A

Summary

UpHealth beats IMAC on 6 of the 9 factors compared between the two stocks.

How does IMAC compare to Better Therapeutics?

IMAC (NASDAQ:BACK) and Better Therapeutics (NASDAQ:BTTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

5.8% of IMAC shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

IMAC has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.10-$9.42M-$3.12N/A
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A

In the previous week, IMAC's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
IMAC Neutral
Better Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
Better Therapeutics N/A N/A N/A

Summary

Better Therapeutics beats IMAC on 5 of the 8 factors compared between the two stocks.

How does IMAC compare to Aclarion?

IMAC (NASDAQ:BACK) and Aclarion (NASDAQ:ACONW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

5.8% of IMAC shares are held by institutional investors. 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Aclarion had 5 more articles in the media than IMAC. MarketBeat recorded 5 mentions for Aclarion and 0 mentions for IMAC. IMAC's average media sentiment score of 0.00 beat Aclarion's score of -0.22 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
Aclarion Neutral

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
Aclarion N/A N/A N/A

Aclarion has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.10-$9.42M-$3.12N/A
Aclarion$77.88KN/AN/AN/AN/A

Summary

IMAC and Aclarion tied by winning 3 of the 6 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

Export
MetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$152K$152K$6.52B$12.05B
Dividend YieldN/AN/A2.67%5.66%
P/E Ratio-0.01N/A24.0024.42
Price / Sales2.102.10515.84118.72
Price / CashN/AN/A27.4837.92
Price / Book-0.06N/A10.606.82
Net Income-$9.42M-$9.42M$3.57B$337.56M
7 Day PerformanceN/AN/A0.59%1.16%
1 Month PerformanceN/AN/A1.54%3.16%
1 Year PerformanceN/AN/A25.41%30.60%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$0.04
flat		N/A-5.9%$152K$72.05KN/A180
DHAC
Digital Health Acquisition
N/A$0.16
-0.6%		N/A-85.9%$562KN/AN/A2,021
NIVF
NewGenIvf Group
2.2452 of 5 stars		$0.56
-2.5%		N/A-99.9%$140K$4.73MN/AN/A
UPHL
UpHealth
N/A$0.00
flat		N/A+50.0%$6K$130MN/A1,750
BTTX
Better Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel